Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 14/20 | 0.80 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343163 | 0.93 | PHGDH (0.70) | PHGDHPTGDRPTGDR2CPT1ACPT1B | |
| SCHEMBL30339239 | 0.89 | PHGDH (1.00) | PHGDHWDR91KDM4EALDH1A1MAPT | |
| SCHEMBL19331467 | 0.89 | PHGDH (1.00) | PHGDHWDR91KDM4EALDH1A1MAPT | |
| SCHEMBL30339583 | 0.89 | PHGDH (0.66) | PHGDHPTGDRPTGDR2CPT1ACPT1B | |
| SCHEMBL19343577 | 0.89 | PHGDH (0.66) | PHGDHPTGDRPTGDR2CPT1ACPT1B | |
| SCHEMBL20793589 | 0.88 | PHGDH (0.68) | PHGDHWDR91PTGDRPTGDR2MAPT | |
| SCHEMBL19343498 | 0.85 | PHGDH (0.61) | PHGDHWDR91KDM4E | |
| SCHEMBL19343477 | 0.85 | PHGDH (0.61) | PHGDH | |
| SCHEMBL30339572 | 0.85 | PHGDH (0.61) | PHGDHWDR91KDM4E | |
| SCHEMBL19343134 | 0.85 | PHGDH (0.59) | PHGDHALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3884939-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3884939-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3884939-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3884939-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3426243-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3426243-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| WO-2017156165-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PHGDH 1/4885WDR91 2575/4885PTGDR 3517/4885 |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885WDR91 2575/4885PTGDR 3517/4885 |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885WDR91 2575/4885PTGDR 3517/4885 |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PHGDH 1/4885WDR91 2575/4885PTGDR 3517/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885WDR91 2575/4885PTGDR 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.